Gynecological Malignancies Group Archives

VHIO’s Josep Tabernero, Enriqueta Felip and Ana Oaknin recognized as Highly Cited Researchers™ 2024

Clarivate™ has revealed the annual list of Highly Cited Researchers™ 2024, curated by its experts at the Institute for Scientific…

Investigational antibody-drug conjugate shows promising efficacy in patients with advanced endometrial or ovarian cancer

The phase 2 multicenter TROPION-PanTumor study was designed to evaluate the efficacy of TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) as…

Immunotherapy added to first-line standard therapy significantly improves survival in metastatic or recurrent cervical cancer

Published in The Lancet, results of the randomized phase III BEATcc academic trial (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) show that adding immune checkpoint…

The promise of novel FolRα-targeting antibody drug conjugate in recurrent epithelial ovarian cancer

Presented today by VHIO’s Ana Oaknin at the 2023 ASCO Annual Meeting, 2-6 June (Chicago, IL), updated dose expansion data…

ESMO Clinical Practice Guideline: consensus recommendations & next directions in the treatment and follow-up of endometrial cancer

Now published in the European Society for Medical Oncology’s (ESMO) flagship journal, Annals of Oncology, ESMO’s Clinical Practice Guideline for…

Cemiplimab steps up as the first immune-based therapy to improve overall survival in patients with recurrent and/or metastatic cervical cancer

Barcelona, May 12, 2021- Cervical cancer is the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death…

Newly appointed ESMO faculty: VHIO investigators join forces with other leading experts in oncology to deliver on ESMO’s Vision 2025

In parallel with the European Society for Medical Oncology’s (ESMO) publication of its 2025 Vision, which builds on the core…